Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alliant Pharmaceuticals, a pediatric specialty pharmaceutical company, plans to sponsor the largest survey ever conducted in the US into attention deficit hyperactivity disorder. The survey will evaluate the satisfaction of patients taking the company's ADHD treatment, Methylin Oral Solution.
Subscribe to our email newsletter
Patient enrollment, which has already begun, will not be completed until March 2006, with up to 10’000 patients being enrolled at over 500 centers. Results from the survey are expected to be available in late 2006.
Methylin Oral Solution is the only liquid medication for ADHD currently available. The oral solution is deigned for patients who have difficulty swallowing tablets or who prefer an easy-to-take liquid formulation. An estimated 26 percent of the total patient population may have difficulty swallowing tablets and capsules. The percentage is estimated higher among children, with child noncompliance a serious problem in the delivery of health care to children.
Art Deas, Alliant vice president, added, “We look forward to the data that the study will provide to both our company and the medical community. We anticipate high marks with regard to satisfaction, convenience and compliance surrounding Methylin Oral Solution.”